LXXGF - LXXGF STOCK NEWS

LexaGene Holdings (OTCQB: LXXGF) announced a significant sale involving two MiQLab® Systems to a large veterinary animal health corporation with over 100 facilities. This purchase marks a pivotal step in expanding the adoption of the MiQLab system, which delivers results on various pathogens and antimicrobial resistance within two hours. CEO Dr. Jack Regan expressed confidence in the technology's value for faster, accurate diagnostics and the potential for wider implementation across the corporation. The sale enhances LexaGene's momentum in the veterinary diagnostics market.

LexaGene Holdings, Inc. (OTCQB: LXXGF) has announced that the U.S. Army Combat Capabilities Development Command has successfully evaluated its MiQLab System for biothreat detection. The evaluation confirmed the system's ability to detect agents such as Bacillus anthracis and Yersinia pestis with high sensitivity and specificity. This follows a Cooperative Research and Development Agreement aimed at developing biothreat defense capabilities. LexaGene’s CEO, Dr. Jack Regan, emphasized the system's effectiveness in using DBPAO's PCR assays.

LexaGene Holdings, a molecular diagnostics firm, announced the sale of three MiQLab Systems to a corporate veterinary reference lab, enhancing rapid pathogen detection in veterinary practices. The MiQLab System offers a 2-hour turnaround for identifying pathogens and drug resistance, significantly faster than traditional methods. Additionally, a unit was sold to a veterinary school in Florida, emphasizing the importance of evidence-based practices in veterinary education. LexaGene also joined AAHA's Strategic Alliance Program, highlighting its commitment to best-in-class veterinary care.

LexaGene Holdings, Inc. announced the results of its 2021 Annual General Special Meeting held on December 16, 2021, where 50,094,097 common shares were voted, representing 41.97% of total outstanding shares. Shareholders approved several key measures including the election of five directors, the appointment of RSM US LLP as auditor, adoption of new articles, and increases in common shares available for conversion of Restricted Share Units and exercise of Options. Detailed voting results for directors were provided, showing strong support across the board.

LexaGene Holdings, a molecular diagnostics company, announces two purchase orders from Kuma Veterinary Clinic and Emergency Veterinary Services of Roanoke for its MiQLab System. This system enables rapid pathogen detection, providing results in approximately two hours, significantly reducing wait times for veterinarians. Dr. Jack Regan, CEO, emphasized the importance of quick diagnostics for improving patient care. LexaGene aims to expand sales in corporate veterinary practices and adapt to new industry standards.

LexaGene Holdings, Inc. (OTCQB: LXXGF) announced plans to pursue 510k clearance and CLIA-waiver from the FDA for its MiQLab System™, designed for syndromic testing at the point of care. The MiQLab allows simultaneous testing for multiple pathogens and antimicrobial resistance, addressing the global threat of drug-resistant infections. The company has opted to discontinue its EUA application for COVID-19 testing to focus on broader pathogen testing instead. With ongoing sales in veterinary and research markets, LexaGene aims to fulfill FDA requirements for human clinical diagnostics.

LexaGene Holdings, a molecular diagnostics company, has announced the appointment of Dr. Jane Sykes to its Board of Directors, effective November 8, 2021. Dr. Sykes, who has extensive experience in veterinary medicine and academia, will replace Dr. Manohar Furtado. The company believes her expertise in infectious diseases and veterinary care will enhance its mission to improve companion animal diagnostics. LexaGene also granted Dr. Sykes 100,000 stock options and 100,000 restricted share units as part of her compensation package.

LexaGene Holdings has expanded its bio-pharmaceutical contamination panel with a new Burkholderia test for its MiQLab™ System. B. cepacia complex is a significant contaminant in nonsterile pharmaceuticals, leading to approximately 39% of contamination incidents. The FDA has recommended that drug manufacturers test for this bacterium due to its role in product recalls. The MiQLab System offers rapid PCR-based testing, which can identify contaminants within hours, significantly reducing potential losses from recalls.

LexaGene Holdings has been recognized as the 2021 BioTech Breakthrough Molecular Diagnostics Solution of the Year. The award highlights LexaGene's innovative MiQLab™ System, designed for automated PCR testing in veterinary diagnostics. Dr. Jack Regan, CEO, noted significant advancements in brand building and product development over the past five years, emphasizing the technology's capability to quickly diagnose infections and detect drug resistance. This recognition reflects the company's potential impact across multiple markets and reinforces their commitment to innovation.